# SOLAR-1 (NCT02437318)

> Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02437318
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Breast Cancer
- Interventions: Fulvestrant; Alpelisib; Placebo
- Enrollment: 572
- Primary outcome: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort

## Commentary we found

- YouTube: 62
- Podcasts: 52
- X threads: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=solar-1-nct02437318

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02437318", "email": "<work email>"}; the inbox owner confirms by the emailed link.